liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension.
AstraZeneca Nordic, Södertälje.
Linköping University, Department of Medical and Health Sciences, Health Technology Assessment and Health Economics. Linköping University, Faculty of Health Sciences.
AstraZeneca Nordic, Södertälje.
2012 (English)In: ClinicoEconomics and outcomes research : CEOR, ISSN 1178-6981, Vol. 4, 313-322 p.Article in journal (Refereed) Published
Abstract [en]

Background: Although angiotensin receptor blockers have different receptor binding properties, no comparative randomized studies with cardiovascular event endpoints have been performed for this class of drugs. The aim of this study was to assess the long-term cost-effectiveness of candesartan (Atacand®) versus generic losartan in the primary preventive treatment of hypertension.Methods: A decision-analytic model was developed to estimate costs and health outcomes over a patient's lifetime. Data from a clinical registry study were used to estimate event rates for cardiovascular complications, such as myocardial infarction and heart failure. Costs and quality of life data were from published sources. Costs were in Swedish kronor and the outcome was quality-adjusted life-years (QALYs). Results: Due to reduced rates of cardiovascular complications, candesartan was associated with a QALY gain and lower health care costs compared with generic losartan (0.053 QALYs gained and reduced costs of approximately 4700 Swedish kronor for women; and 0.057 QALYs gained and reduced costs of approximately 4250 Swedish kronor for men). This result was robust in several sensitivity analyses.Conclusion: When modeling costs and health outcomes based on event rates for cardiovascular complications from a real-world registry study, candesartan appears to bring a QALY gain and a reduction in costs compared with generic losartan in the primary preventive treatment of hypertension in Sweden.

Place, publisher, year, edition, pages
Dove Medical Press , 2012. Vol. 4, 313-322 p.
Keyword [en]
hypertension, angiotensin receptor blockers, cost-effectiveness, decision analysis
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-87725DOI: 10.2147/CEOR.S35824OAI: oai:DiVA.org:liu-87725DiVA: diva2:600039
Available from: 2013-01-23 Created: 2013-01-22 Last updated: 2014-03-06

Open Access in DiVA

fulltext(368 kB)255 downloads
File information
File name FULLTEXT01.pdfFile size 368 kBChecksum SHA-512
2b20c884e7181c48332952657d318d236c34e489fdfdff670cbf5f23974b9667696082963cbdf156d556631abcede8cdfe90ba88c72fa4679f3490a96d9a26b9
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Levin, Lars-Åke

Search in DiVA

By author/editor
Levin, Lars-Åke
By organisation
Health Technology Assessment and Health EconomicsFaculty of Health Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 255 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 68 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf